The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Ozempic, a drug for diabetes and weight loss, continues to be the talk of the town. Recently, the US Food and Drug ...

It showed that 1 mg Ozempic led to a 24 per cent reduced risk of worsening kidney disease and kidney failure (end-stage ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

In the US, 1 in 7 adults are experiencing some type of chronic kidney disease caused by diabetes. The new approval therefore allows doctor to prescribe Ozempic to lower the risk of kidney failure, ...

The FDA approval is based on results from a trial investigating the effects of once-a-week Ozempic injections on major kidney ...

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...